Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

30 Nov 2005 07:04

Original Investments PLC30 November 2005 Original Investments PLC ("Original Investments" or "the Company") Acrobot update An innovative medical device, enabling orthopaedic surgeons to accurately planand perform hip resurfacing surgery, has been granted a CE-mark by BSI'sCertification Panel. The surgical navigation product has been developed by TheAcrobot Company ("Acrobot") in which Original Investments, the AIM-quotedinvestment company, has a 25% shareholding. The device has been developed incollaboration with Corin Group PLC ("Corin"), and the CE-mark is themanufacturer's guarantee that the device meets all the required Europeanmanufacturing and safety standards. Acrobot develops surgical systems for minimally-invasive, bone-conservingorthopaedic surgery. The new device, called Acrobot(R) Navigation, is beingcommercialised by Corin, under the name of Wayfinder(R), to enable accurateimplantation of the company's metal on metal hip resurfacing implant.Clinical trials are to start immediately at a London hospital. Justin Cobb,Professor of Orthopaedics at Imperial College, will lead the alpha site. Twoadditional sites in the UK and a third in Australia will start evaluation of theAcrobot(R) Navigation system in the second quarter of 2006. The device will bein wider use from the second half of 2006. The Acrobot(R) Navigation system gives the surgeon the ability to accuratelyimplant hip resurfacing prostheses in a minimally invasive procedure. It differsfrom competitive products by using mechanical tracking rather than optical orelectromagnetic technologies, giving it a higher accuracy at a lower cost.Acrobot believes that this unique selling point will increase the use of thetechnology, making it accessible to a larger number of surgeons and patients.The Acrobot(R) Navigation system has been developed by the Acrobot team at thecompany's laboratories in London. Acrobot is seeking licensees and distributorsfor applications of Navigation to other orthopaedic procedures. It is the secondof a number of related products to be produced by Acrobot, having launched theAcrobot(R) Planner software and service last month. A third product planned forlaunch in 2006 is the Acrobot(R) Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. Enquiries to: Dr. Paula Gomes, Director of OperationsThe Acrobot Company Ltd, Tel: +44 (0)20 7403 5866, Email:enquiries@acrobot.co.ukor Terry Bond, Managing Director, Original Investments PLC 44 (0) 1235 834734.Email: tb@originalinvestments.com About The Acrobot Company Ltd The Acrobot Company Ltd develops precision surgical systems for minimallyinvasive, bone conserving, orthopaedic surgery. The Company was founded sixyears ago by Imperial Innovations as a collaboration to combine the skills ofclinicians and academics Using proprietary surgical planning software andstate-of-the-art Hands-On Robotics(TM), and Passive Constraint Navigation(TM)systems, Acrobot's products assist surgeons in achieving better patient outcomesby improving surgical precision and reducing surgical errors, while loweringoverall procedure cost. About Original Investments PLC Original Investments PLC, formerly called BioProjects International PLC, isquoted on the AIM market of the London Stock Exchange. The Company specializesin providing finance for early-stage companies that can demonstrate immediategrowth prospects and significant financial potential. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.